Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Read More

Ligand Reports First Quarter 2023 Financial Results

Read More

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

Read More

Recent Events

Upcoming Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range